Respiratory Medicine at Shanghai Pulmonary Hospital | CMCS

Expert Respiratory Care at China's Premier Pulmonary Specialty Hospital

The Department of Respiratory Medicine at Shanghai Pulmonary Hospital — affiliated with Tongji University — is one of China's most distinguished respiratory medicine centers, with a national reputation for excellence in interstitial lung disease, COPD, pulmonary hypertension, respiratory infections, sleep-disordered breathing, and the management of complex respiratory conditions. As China's premier dedicated pulmonary specialty hospital, the respiratory medicine department benefits from unparalleled integration with thoracic surgery, pulmonary oncology, interventional pulmonology, and lung transplantation — offering international patients a uniquely comprehensive respiratory care experience under one roof. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their respiratory care journey at Shanghai Pulmonary Hospital.

About the Department

The respiratory medicine department is a national key clinical specialty operating dedicated respiratory inpatient wards, a respiratory intensive care unit (RICU), a pulmonary function laboratory, a bronchoscopy suite, a sleep medicine laboratory, an interstitial lung disease center, a COPD management clinic, a pulmonary hypertension clinic, a respiratory infection clinic, and works in close collaboration with thoracic surgery, pulmonary oncology, interventional pulmonology, lung transplantation, and rheumatology through a fully integrated multidisciplinary team.

Interstitial Lung Disease (ILD)

Shanghai Pulmonary Hospital's ILD program is one of China's most comprehensive and nationally recognized:

Idiopathic Interstitial Pneumonias

• Idiopathic Pulmonary Fibrosis (IPF) — Nintedanib (Ofev); pirfenidone (Esbriet); inhaled treprostinil (Tyvaso) for IPF with pulmonary hypertension; sildenafil for IPF-PH; lung transplantation evaluation; oxygen therapy; pulmonary rehabilitation; one of China's most experienced IPF programs
• Progressive Pulmonary Fibrosis (PPF) — Nintedanib for non-IPF progressive fibrotic ILD (INBUILD trial); SSc-ILD; RA-ILD; NSIP; unclassifiable ILD with progressive fibrosis
• Non-Specific Interstitial Pneumonia (NSIP) — Corticosteroids; mycophenolate; azathioprine; nintedanib for fibrotic NSIP
• Cryptogenic Organizing Pneumonia (COP) — Corticosteroids; macrolide antibiotics; relapse management
• Acute Interstitial Pneumonia (AIP/Hamman-Rich) — High-dose corticosteroids; cyclophosphamide; ECMO for refractory respiratory failure; coordination with lung transplantation
• Respiratory Bronchiolitis-ILD & DIP — Smoking cessation; corticosteroids

Connective Tissue Disease-ILD

• SSc-ILD — Nintedanib (SENSCIS trial); tocilizumab (focuSSced trial); rituximab; cyclophosphamide; mycophenolate; autologous HSCT for severe SSc
• RA-ILD — Nintedanib (INBUILD); abatacept; rituximab; mycophenolate; avoidance of methotrexate in active ILD
• PM/DM-ILD — Anti-MDA5 antibody-associated rapidly progressive ILD; high-dose corticosteroids + calcineurin inhibitor + rituximab; plasma exchange; JAK inhibitors (tofacitinib, baricitinib) for refractory MDA5-ILD; one of China's most experienced MDA5-ILD programs
• Sjögren's-ILD — Corticosteroids; hydroxychloroquine; mycophenolate; rituximab
• MCTD-ILD — Corticosteroids; mycophenolate; nintedanib

Hypersensitivity Pneumonitis (HP)

• Antigen identification and avoidance; corticosteroids for acute HP; mycophenolate; azathioprine; nintedanib for fibrotic HP; lung transplantation for end-stage fibrotic HP

Sarcoidosis

• Corticosteroids; methotrexate; azathioprine; hydroxychloroquine; infliximab for refractory pulmonary and extrapulmonary sarcoidosis; cardiac sarcoidosis coordination with cardiology

Rare ILDs

• Lymphangioleiomyomatosis (LAM) — Sirolimus (MILES trial); lung transplantation for advanced LAM; VEGF-D monitoring
• Pulmonary Alveolar Proteinosis (PAP) — Whole lung lavage (WLL); GM-CSF inhalation; rituximab for autoimmune PAP; one of China's most experienced WLL programs
• Pulmonary Langerhans Cell Histiocytosis (PLCH) — Smoking cessation; cladribine; vemurafenib for BRAF V600E-mutated LCH
• Eosinophilic Pneumonia — Corticosteroids; mepolizumab for chronic eosinophilic pneumonia; benralizumab

COPD & Emphysema

• COPD Assessment & Phenotyping — Spirometry; GOLD staging; CT emphysema quantification; air trapping; small airways disease; COPD-X phenotype; exacerbation history; eosinophil count
• Inhaler Therapy — LAMA + LABA combinations; ICS + LABA + LAMA triple therapy (Trelegy Ellipta, Breztri Aerosphere); inhaler technique optimization; device selection
• Biologic Therapy — Dupilumab for COPD with type 2 inflammation (eosinophil ≥300 — BOREAS and NOTUS trials); itepekimab (anti-IL-33) for COPD; tezepelumab
• Bronchoscopic Lung Volume Reduction — Endobronchial valves (Zephyr EBV) for severe emphysema with intact fissures; one of China's most experienced EBV programs; coils; thermal vapor ablation
• Pulmonary Rehabilitation — Exercise training; breathing techniques; nutritional support; psychosocial support; coordination with rehabilitation medicine
• Acute Exacerbation Management — Systemic corticosteroids; antibiotics; bronchodilators; NIV (BiPAP) for hypercapnic respiratory failure; HFNO; ICU coordination

Pulmonary Hypertension

Shanghai Pulmonary Hospital's pulmonary hypertension program is one of China's most comprehensive:

• Pulmonary Arterial Hypertension (PAH) — ERA + PDE5i + prostacyclin triple combination; sotatercept (Winrevair — STELLAR trial) for PAH; selexipag; IV epoprostenol; subcutaneous treprostinil; inhaled iloprost; macitentan + tadalafil (AMBITION); upfront combination therapy; one of China's most experienced PAH programs
• CTEPH — Riociguat (CHEST-1); balloon pulmonary angioplasty (BPA) for inoperable CTEPH; pulmonary endarterectomy (PEA) coordination; macitentan for CTEPH
• Group 3 PH (ILD-PH) — Inhaled treprostinil (INCREASE trial) for ILD-PH; treatment of underlying ILD; oxygen therapy
• Diagnostic Workup — Right heart catheterization; vasoreactivity testing; V/Q scan for CTEPH; CT pulmonary angiography; echocardiography; 6MWT; BNP/NT-proBNP; genetic testing (BMPR2, ACVRL1, ENG)

Respiratory Infections

• Community-Acquired Pneumonia (CAP) — Severity assessment (PSI, CURB-65); beta-lactam + macrolide; respiratory fluoroquinolone; severe CAP: beta-lactam + macrolide + corticosteroids; Legionella and pneumococcal urinary antigen; RICU for severe CAP
• Hospital-Acquired & Ventilator-Associated Pneumonia — Culture-directed antibiotics; anti-MRSA (vancomycin, linezolid, ceftaroline); anti-Pseudomonal; cefiderocol for MDR gram-negative; ceftazidime-avibactam for KPC-producing Klebsiella
• Bronchiectasis — Airway clearance (ACBT, oscillating PEP, HFCWO); inhaled antibiotics (tobramycin, colistin, aztreonam) for chronic Pseudomonas; macrolide maintenance; brensocatib (DPP-1 inhibitor) for bronchiectasis exacerbation prevention; one of China's most experienced bronchiectasis programs
• Non-Tuberculous Mycobacteria (NTM) — MAC lung disease: azithromycin + rifampicin + ethambutol; amikacin liposome inhalation suspension (ALIS — Arikayce) for refractory MAC; M. abscessus: amikacin + imipenem + azithromycin; phage therapy for M. abscessus; one of China's most experienced NTM programs
• Invasive Fungal Infections — Aspergillosis: voriconazole; isavuconazole; liposomal amphotericin B; olorofim for azole-resistant Aspergillus; PCP: TMP-SMX; Cryptococcus: fluconazole; amphotericin B + flucytosine
• Post-COVID Respiratory Complications — Post-COVID ILD; pulmonary fibrosis; exercise intolerance; breathlessness; pulmonary rehabilitation

Sleep-Disordered Breathing

• Obstructive Sleep Apnea (OSA) — Polysomnography; home sleep testing; CPAP; auto-CPAP; BiPAP; mandibular advancement device; hypoglossal nerve stimulation (Inspire) coordination; positional therapy; weight management
• Obesity Hypoventilation Syndrome (OHS) — NIV (BiPAP); weight loss; bariatric surgery coordination
• Central Sleep Apnea — Adaptive servo-ventilation (ASV); treatment of underlying cause

Mechanical Ventilation & Respiratory Failure

• Non-Invasive Ventilation (NIV) — BiPAP for COPD exacerbation; hypercapnic respiratory failure; OHS; neuromuscular disease; home NIV
• High-Flow Nasal Oxygen (HFNO) — For hypoxemic respiratory failure; post-extubation; COVID-19 pneumonia
• RICU Care — Invasive mechanical ventilation; lung-protective ventilation; prone positioning for ARDS; ECMO coordination with lung transplantation for refractory ARDS

Why International Patients Choose Shanghai Pulmonary Hospital Respiratory Medicine

• ILD Center of Excellence — One of China's most comprehensive ILD programs; anti-MDA5 rapidly progressive ILD expertise; nintedanib for PPF
• Sotatercept for PAH — Novel activin receptor ligand trap; STELLAR trial evidence; superior to ERA + PDE5i alone
• Endobronchial Valve (Zephyr) — One of China's most experienced EBV programs for severe emphysema
• ALIS (Arikayce) for MAC — Amikacin liposome inhalation suspension for refractory MAC lung disease
• Brensocatib for Bronchiectasis — DPP-1 inhibitor for bronchiectasis exacerbation prevention
• Whole Lung Lavage for PAP — One of China's most experienced WLL programs for pulmonary alveolar proteinosis
• Cost-Effectiveness — World-class respiratory care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your respiratory diagnosis, pulmonary function tests, CT chest imaging, bronchoscopy reports, sleep study results, and current medications with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate respiratory physician based on your condition — ILD, COPD, pulmonary hypertension, respiratory infection, NTM, or sleep apnea.
4. Priority Scheduling — We secure a consultation with minimal waiting time.
5. Travel & Logistics — Assistance with visa invitation letters, accommodation near Shanghai Pulmonary Hospital, and Shanghai airport transfers.
6. Diagnostic Assessment — Full coordination of pulmonary function testing, CT chest, bronchoscopy, BAL, surgical lung biopsy, right heart catheterization, and sleep study.
7. Treatment Coordination — Full coordination of antifibrotic therapy initiation, biologic therapy, bronchoscopic procedures, NIV setup, and PAH treatment.
8. Post-Consultation Follow-Up — Test result translation, treatment plan interpretation, and remote follow-up coordination after you return home.

Book a Consultation

If you have interstitial lung disease, COPD, pulmonary hypertension, a respiratory infection, NTM lung disease, bronchiectasis, or a complex respiratory condition — CMCS can arrange a specialist consultation with Shanghai Pulmonary Hospital's respiratory medicine team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com